The transaction includes $70m in cash and a $20m retained equity position for Nektar in a new Ampersand portfolio company.
On Monday, Nektar Therapeutics (NKTR) stock saw a modest uptick, ending the day at $1.33 which represents a slight increase of $0.10 or 8.13% from the prior close of $1.23. The stock opened at $1.37 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback